Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 20/20 | 0.40 |
| ▸ | TLR7 | Q9NYK1 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23289369 | 0.91 | DRD2 (0.34) | TLR8TLR7 | |
| SCHEMBL28865830 | 0.89 | TLR8 (0.43) | TLR8TLR7 | |
| SCHEMBL23289302 | 0.84 | TLR8 (0.46) | TLR8TLR7 | |
| SCHEMBL23273931 | 0.84 | TLR8 (0.42) | TLR8TLR7 | |
| SCHEMBL23289305 | 0.84 | TLR8 (0.42) | TLR8TLR7 | |
| SCHEMBL23289301 | 0.84 | TLR8 (0.42) | TLR8TLR7 | |
| SCHEMBL23274145 | 0.83 | TLR8 (0.42) | TLR8TLR7 | |
| SCHEMBL22783801 | 0.83 | TLR8 (0.51) | TLR8TLR7 | |
| SCHEMBL23289304 | 0.82 | TLR8 (0.46) | TLR8TLR7 | |
| SCHEMBL23289341 | 0.82 | TLR8 (0.41) | TLR8TLR7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12465653-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2025-11-11 | — | — | US | disclosed |
| EP-4048315-B1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS INC (US) | 2025-03-12 | — | — | EP | disclosed |
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230257393-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257393-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-20230257393-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-08-17 | — | — | US | disclosed |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | BOLT BIOTHERAPEUTICS, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| EP-4048314-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| EP-4048315-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | Bolt Biotherapeutics, Inc. (US) | 2022-08-31 | — | — | EP | disclosed |
| US-20210128744-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| US-20210128744-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-05-06 | — | — | US | disclosed |
| WO-2021081407-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021081407-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021081402-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
| WO-2021081402-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | BOLT BIOTHERAPEUTICS, INC. (US) | 2021-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338571-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | ICOS, CYP3A5, TPH1 | TLR8 3844/4885TLR7 2077/4885 |
| US-12465653-B2 | Thienoazepine immunoconjugates, and uses thereof | ICOS, CYP3A5, TPH1 | TLR8 3844/4885TLR7 2077/4885 |
| US-11654199-B2 | Thienoazepine immunoconjugates, and uses thereof | ICOS, CYP3A5, TPH1 | TLR8 3844/4885TLR7 2077/4885 |
| US-20230257393-A1 | MACROMOLECULE-SUPPORTED THIENOAZEPINE COMPOUNDS, AND USES THEREOF | HTR3D, PNMT, HTR3B | TLR8 4164/4885TLR7 4231/4885 |
| US-20210128744-A1 | THIENOAZEPINE IMMUNOCONJUGATES, AND USES THEREOF | ICOS, CYP3A5, TPH1 | TLR8 3844/4885TLR7 2077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.